CV6 Therapeutics is an early-stage drug development company that is dedicated to improving the treatment options for cancer patients. With over 25 years of research experience, the company focuses on identifying molecular vulnerabilities in cancer cells and developing innovative therapeutics to target them. Their groundbreaking research has resulted in the discovery of novel drug targets that serve as the foundation for their innovative strategies.

CV6 Therapeutics was established in 2013 with the goal of expediting the development of these targeted small molecule therapeutics. Their first oncology drug, CV6-168, has successfully completed pre-clinical development and is set to enter a first-in-human clinical trial in 2023. As a drug development company, CV6 Therapeutics is dedicated to the discovery, development, and commercialization of novel combination therapies.

Their mission is to revolutionize cancer treatment and enhance the lives of patients and their families. With a strong commitment to innovation and scientific excellence, CV6 Therapeutics strives to make a significant impact in the fight against cancer